Across 142 European CTIS infectious disease Phase 3 trials authorised in 2024–2026, CRO or outsourced provider support appeared in 42 trials, or 29.6%. Demand concentrated sharply in multi-country, high-participant, pharma-sponsored, orphan, and paediatric studies: CRO-supported trials represented 197 of 328 country-level CTIS submissions, 60.1%, and 47,104 of 84,474 planned participants, 55.8%.
Among the 42 trials with CRO/provider support, PPD / Thermo Fisher appeared in 20 trials, 47.6%. The next most active organizations were ICON / PRA in 9 trials, 21.4%, Parexel in 8 trials, 19.0%, and IQVIA in 7 trials, 16.7%.
The CRO market in this CTIS infectious disease cohort is concentrated but not monopolized. PPD / Thermo Fisher had the broadest footprint, while ICON / PRA, Parexel, IQVIA, Syneos, and specialist technology or lab providers formed the next layer of recurring support.
Only 6 of 93 single-country trials used CRO/provider support, 6.5%. By contrast, 12 of 13 trials spanning 6–10 countries used support, 92.3%, and both trials spanning 11 or more countries used support, 100.0%.
The clearest operational trigger for CRO use is CTIS scale: more countries, more sites, and more participants. Median CRO-supported trials had 4 countries, 24.5 sites, and 382.5 planned participants, compared with 1 country, 9 sites, and 210 participants in trials without CRO/provider support.
HIV-1 infection had the highest absolute CRO-supported trial count, with 13 of 19 trials supported, 68.4%. Hepatitis D had 5 of 7 supported trials, 71.4%, while Group B streptococcus disease had 3 of 3 supported trials, 100.0%, and COVID-19 / SARS-CoV-2 had 4 of 12, 33.3%.
| Indication | Supported / total | Rate |
|---|---|---|
| Group B streptococcus disease | 3 / 3 | 100.0% |
| Hepatitis D | 5 / 7 | 71.4% |
| HIV-1 infection | 13 / 19 | 68.4% |
| COVID-19 / SARS-CoV-2 | 4 / 12 | 33.3% |
| Respiratory syncytial virus | 2 / 6 | 33.3% |
| Influenza | 1 / 5 | 20.0% |
CRO demand is strongest where the operational model requires global enrolment, virology testing, large safety follow-up, paediatric consent logistics, or rare-disease execution. HIV and hepatitis D are recurring outsourced markets; Group B streptococcus has fewer trials but unusually high capacity demand.
CRO-supported trials generated 197 of 328 CTIS country-level tracks, 60.1%. Spain appeared in 28 CRO-supported trial-country records, Germany in 25, and France in 21; by site volume, Spain led with 218 CRO-supported sites, followed by France with 170 and Germany with 169.
For CROs selling infectious disease Phase 3 support, Spain, Germany, France, Italy, Belgium, and Poland are the highest-priority CTIS execution markets. These countries combine repeated trial participation with meaningful site and participant volume, making them strong targets for submissions, site activation, monitoring, and country operations capacity.
Third-party support appeared in 65 of 142 trials, 45.8%. Among those 65 outsourced trials, central lab or bioanalytical testing appeared in 38, 58.5%, clinical operations/CRO services in 37, 56.9%, and digital trial systems, eCOA, or data tools in 24, 36.9%.
The most outsourced functions are not only full-service CRO operations. Infectious disease Phase 3 trials frequently need central lab, virology, sample logistics, eCOA, safety, and patient-support infrastructure, especially when CTIS submissions span multiple countries and local operational documents.
Pharmaceutical company sponsors used CRO/provider support in 40 of 57 trials, 70.2%, compared with 1 of 64 hospital or clinic-sponsored trials, 1.6%. Orphan infectious disease trials used support in 9 of 11 trials, 81.8%, and paediatric trials used support in 20 of 35 trials, 57.1%.
For business development, the strongest target profile is a pharma-sponsored infectious disease Phase 3 trial entering Europe through CTIS, especially if it is orphan, paediatric, vaccine-related, virology-heavy, or spread across multiple EU/EEA countries. Single-country academic and hospital-sponsored trials show far lower outsourced-provider penetration.
CRO/provider support means at least one organization was listed in the trial’s CRO-present field. CTIS means the Clinical Trials Information System used for EU/EEA clinical trial submissions. Part II refers to country-level assessment and authorization components. IMP means investigational medicinal product. eCOA means electronic clinical outcome assessment.